In a report released today, Difei Yang from Mizuho Securities reiterated a Hold rating on Abeona Therapeutics (ABEO), with a price target of $4.00. The company’s shares closed last Tuesday at $2.91.
According to TipRanks.com, Yang has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -9.5% and a 34.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Sarepta Therapeutics, and Revance Therapeutics.
Abeona Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $7.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.19 and a one-year low of $1.35. Currently, Abeona Therapeutics has an average volume of 891.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.
